Overview

Tranexamic Acid for Prevention of Postpartum Haemorrhage: a Dose-finding Study

Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
0
Participant gender:
Female
Summary
Published trials on tranexamic acid (TxA) for prevention have used a variety of fixed (0.5gm or 1gm) and body-weight adjusted (10mg/kg or 15mg/kg) doses of TxA. Given the wide range of bodyweights of pregnant women in contemporary obstetric practice, it is critical to determine the minimum effective dose of TxA, so as to avoid under- or over-dosing. The rationale of this study is to determine the minimum effective dose of TxA that is required to attain therapeutic plasma levels of TxA, established at 5-15mg/L, following administration of a single dose of intravenous (IV) TxA after childbirth and the clamping the umbilical cord, and before delivery of the placenta. Following birth of the infant, and upon clamping the umbilical cord, the investigators will administer a single dose of IV TxA in 100ml of 0.9% sodium chloride at 50mg/min according to the dose-escalation schedule described below. The slow rate of infusion has been chosen to prevent untoward effects such as hypotension that have been noted when the rate of infusion has exceeded 100mg/min. As part of the dose-escalation design, the investigators will start with 5mg/kg, half the smallest described dose, on a sample of up to 5 women. They will continue to administer TxA doses in increments of 5mg/kg to each successive batch of 5 women. If the number of treatment successes cannot statistically rule out a value < 75% (< 4 of 5 women are successes due to values in the low range), the dose will be increased by 5mg/kg for the next set of 5 women, and so on, until a maximum dose of 30mg/kg is reached, a dose deemed safe based on earlier studies in different populations. Once treatment success is determined at a certain dose, i.e. 4/5 women have levels in the therapeutic range), a total of 20 women will be administered that dose to ensure that 75% i.e. 18/20 women are successes at that dose.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mount Sinai Hospital, Canada
Collaborators:
Canadian Institutes of Health Research (CIHR)
Sinai Health System
University Health Network, Toronto
University of Toronto
University of Waterloo
Treatments:
Tranexamic Acid
Criteria
Inclusion Criteria:

- Women 18 years of age or greater

- Pregnant with a single fetus

- Undergoing planned caesarean delivery for a non-medical indication

- ≥ 37 completed weeks of gestation

Exclusion Criteria:

- Contraindications to use of TxA (i.e. acute arterial/venous thrombosis,
hypersensitivity to TxA, history of seizures, moderate to severe renal failure from
any condition, defective colour vision, subarachnoid haemorrhage and disseminated
intravascular coagulation (abnormally increased activation of pro-coagulant pathways))

- Medical conditions that could influence bleeding and/or the pharmacokinetics of TxA
(i.e. personal/family history of bleeding disorders, receipt of warfarin seven days or
heparin 24 hours prior to caesarean delivery, hypertensive disorders of pregnancy,
need for intra- or post-operative blood transfusions and postpartum
thromboprophylaxis)

- Women with morbidly adherent placentae scheduled for planned caesarean-hysterectomies

- Use of concomitant medications that could result in drug interactions
(hydrochlorothiazide, desmopressin, sulbactam-ampicillin, carbazochrome, ranitidine or
nitroglycerin)